[
  {
    "ts": "2026-01-28T08:05:19+00:00",
    "headline": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
    "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f05cc752-0116-35e1-a12f-dac8d7f86a34",
      "content": {
        "id": "f05cc752-0116-35e1-a12f-dac8d7f86a34",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
        "description": "",
        "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
        "pubDate": "2026-01-28T08:05:19Z",
        "displayTime": "2026-01-28T08:05:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L6CMpFrYeopyfVnnz0zZAA--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vVDSbH1T4crsVM0rpSIWSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:06:53+00:00",
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows.",
    "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
      "content": {
        "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
        "contentType": "STORY",
        "title": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
        "description": "",
        "summary": "Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows.",
        "pubDate": "2026-01-28T11:06:53Z",
        "displayTime": "2026-01-28T11:06:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y8.BnBtGUxBECcC9nPAbmg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSVI8paIUF0YaI3N8PMZkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:48:58+00:00",
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "62d39b3a-c971-3378-8437-69454e7eb072",
      "content": {
        "id": "62d39b3a-c971-3378-8437-69454e7eb072",
        "contentType": "STORY",
        "title": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
        "description": "",
        "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
        "pubDate": "2026-01-28T12:48:58Z",
        "displayTime": "2026-01-28T12:48:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C1nJneUQiExdSmoCae_JSg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63PlXOZomCP8u1XunFvtlg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cms-selects-next-batch-15-124858672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "TAK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:03:20+00:00",
    "headline": "Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless",
    "summary": "drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, ​the Germany-based startup said on Wednesday, to develop and commercialize ‌treatments for hearing loss using the biotech's gene-editing platform.",
    "url": "https://finance.yahoo.com/news/eli-lilly-signs-1-12-120320602.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "77f602d9-9a75-3aa9-8c02-5b20adbe3565",
      "content": {
        "id": "77f602d9-9a75-3aa9-8c02-5b20adbe3565",
        "contentType": "STORY",
        "title": "Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless",
        "description": "",
        "summary": "drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, ​the Germany-based startup said on Wednesday, to develop and commercialize ‌treatments for hearing loss using the biotech's gene-editing platform.",
        "pubDate": "2026-01-28T12:03:20Z",
        "displayTime": "2026-01-28T12:03:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/3d4f11ea41567b93a3b2696680e524a5",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EEXTHwMXlIsCsNAMLidOkw--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3d4f11ea41567b93a3b2696680e524a5.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rSZ.wLMbqjyjcjmBjTgODA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3d4f11ea41567b93a3b2696680e524a5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-signs-1-12-120320602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-signs-1-12-120320602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VERV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:00:00+00:00",
    "headline": "Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss",
    "summary": "-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders -- -- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications -- Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global re",
    "url": "https://finance.yahoo.com/news/seamless-therapeutics-announces-global-research-120000710.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3f8b2c8c-edeb-3251-a69f-eb6787ccc266",
      "content": {
        "id": "3f8b2c8c-edeb-3251-a69f-eb6787ccc266",
        "contentType": "STORY",
        "title": "Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss",
        "description": "",
        "summary": "-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders -- -- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications -- Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global re",
        "pubDate": "2026-01-28T12:00:00Z",
        "displayTime": "2026-01-28T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/a828aa8226a8992f24eab1262ba24250",
          "originalWidth": 1406,
          "originalHeight": 492,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BRFzeerGtUkgEsX7nrfgtg--~B/aD00OTI7dz0xNDA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a828aa8226a8992f24eab1262ba24250.cf.webp",
              "width": 1406,
              "height": 492,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ql5uuS687aNvj0DGkzJLJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a828aa8226a8992f24eab1262ba24250.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/seamless-therapeutics-announces-global-research-120000710.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/seamless-therapeutics-announces-global-research-120000710.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:31:21+00:00",
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
    "url": "https://ca.finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
      "content": {
        "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
        "contentType": "STORY",
        "title": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
        "description": "",
        "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
        "pubDate": "2026-01-28T11:31:21Z",
        "displayTime": "2026-01-28T11:31:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y8.BnBtGUxBECcC9nPAbmg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSVI8paIUF0YaI3N8PMZkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:31:18+00:00",
    "headline": "India Obesity Drug Fight Is About to Intensify",
    "summary": "Sun Pharma clears path for semaglutide generics",
    "url": "https://finance.yahoo.com/news/india-obesity-drug-fight-intensify-113118752.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "78fe8473-8b34-3a24-a5a9-3e297ace4b67",
      "content": {
        "id": "78fe8473-8b34-3a24-a5a9-3e297ace4b67",
        "contentType": "STORY",
        "title": "India Obesity Drug Fight Is About to Intensify",
        "description": "",
        "summary": "Sun Pharma clears path for semaglutide generics",
        "pubDate": "2026-01-28T11:31:18Z",
        "displayTime": "2026-01-28T11:31:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/india-obesity-drug-fight-intensify-113118752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/india-obesity-drug-fight-intensify-113118752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SUNPHARMA.BO"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:25:59+00:00",
    "headline": "Eikon ‍Therapeutics targets $908 million valuation in US IPO",
    "summary": "Jan 28 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.",
    "url": "https://finance.yahoo.com/news/eikon-therapeutics-targets-908-million-111855370.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ea455414-0119-3a3b-a58e-acc9cc892170",
      "content": {
        "id": "ea455414-0119-3a3b-a58e-acc9cc892170",
        "contentType": "STORY",
        "title": "Eikon ‍Therapeutics targets $908 million valuation in US IPO",
        "description": "",
        "summary": "Jan 28 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.",
        "pubDate": "2026-01-28T11:25:59Z",
        "displayTime": "2026-01-28T11:25:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/15ccdbe3e35fba06e62bc2faa0d8466b",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: The Wall Street sign hangs outside the New York Stock Exchange (NYSE) building in New York City, U.S., March 11, 2025. REUTERS/Shannon Stapleton/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zjzGmXYNPXWDjnYrSeEtfg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/15ccdbe3e35fba06e62bc2faa0d8466b.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N5qDmhD4W.avDzw32ya2Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/15ccdbe3e35fba06e62bc2faa0d8466b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eikon-therapeutics-targets-908-million-111855370.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eikon-therapeutics-targets-908-million-111855370.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:03:14+00:00",
    "headline": "Here’s Why Eli Lilly (LLY) is Surging",
    "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can be downloaded here. Global equity markets delivered robust results in the quarter, backed by easing inflation trends and strong economic data. The Hardman Johnston Global Equity Strategy […]",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-surging-130314523.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9adf82db-c903-3537-8a6d-5253d0fa69c5",
      "content": {
        "id": "9adf82db-c903-3537-8a6d-5253d0fa69c5",
        "contentType": "STORY",
        "title": "Here’s Why Eli Lilly (LLY) is Surging",
        "description": "",
        "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can be downloaded here. Global equity markets delivered robust results in the quarter, backed by easing inflation trends and strong economic data. The Hardman Johnston Global Equity Strategy […]",
        "pubDate": "2026-01-28T13:03:14Z",
        "displayTime": "2026-01-28T13:03:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DFQyzS.MgxX7FGup4wuuQQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lop4Pg7FGZ0GE4bKJLODDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-surging-130314523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-surging-130314523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:43:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "1131 GMT – Roche Holding’s results from a midstage study of its CT-388 obesity drug candidate look promising, UBS analysts say in a research note.  The drug the Swiss pharmaceutical company is developing achieved weight-loss efficacy that seems to be broadly similar to Eli Lilly’s Zepbound, but at an earlier timepoint, and the discontinuation rate looks similar too, UBS says.  “All that said, the weight loss looks robust and the safety profile looks generally consistent with the drug class.”",
    "url": "https://www.wsj.com/business/health-care-roundup-market-talk-76913f76?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "6170735c-d296-3b53-a334-ffdd5ffd2e91",
      "content": {
        "id": "6170735c-d296-3b53-a334-ffdd5ffd2e91",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "1131 GMT – Roche Holding’s results from a midstage study of its CT-388 obesity drug candidate look promising, UBS analysts say in a research note.  The drug the Swiss pharmaceutical company is developing achieved weight-loss efficacy that seems to be broadly similar to Eli Lilly’s Zepbound, but at an earlier timepoint, and the discontinuation rate looks similar too, UBS says.  “All that said, the weight loss looks robust and the safety profile looks generally consistent with the drug class.”",
        "pubDate": "2026-01-28T11:43:00Z",
        "displayTime": "2026-01-28T11:43:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6170735c-d296-3b53-a334-ffdd5ffd2e91/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/584f487d9febfcdcb9dec8d0905b588d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7C8N0J6U82R5zJhMhfEY2g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/584f487d9febfcdcb9dec8d0905b588d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gox2xigzu11PPu88Phespw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/584f487d9febfcdcb9dec8d0905b588d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/health-care-roundup-market-talk-76913f76?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:11:47+00:00",
    "headline": "Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets",
    "summary": "Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene editing therapies for hearing loss. The company also received FDA Breakthrough Therapy designation for an antibody drug conjugate in ovarian cancer. Both developments expand Lilly’s pipeline into genetic hearing loss and oncology, beyond its current strength in diabetes and obesity treatments. Eli Lilly, best known to many investors for its diabetes and obesity portfolio,...",
    "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-141147815.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "15923aa2-3f29-3879-bc52-3c983d8aa1d6",
      "content": {
        "id": "15923aa2-3f29-3879-bc52-3c983d8aa1d6",
        "contentType": "STORY",
        "title": "Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets",
        "description": "",
        "summary": "Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene editing therapies for hearing loss. The company also received FDA Breakthrough Therapy designation for an antibody drug conjugate in ovarian cancer. Both developments expand Lilly’s pipeline into genetic hearing loss and oncology, beyond its current strength in diabetes and obesity treatments. Eli Lilly, best known to many investors for its diabetes and obesity portfolio,...",
        "pubDate": "2026-01-28T14:11:47Z",
        "displayTime": "2026-01-28T14:11:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-141147815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-141147815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:00:55+00:00",
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,039.51 as of January 27th. LLY’s trailing and forward P/E were 50.93 and 31.65 respectively according to Yahoo Finance. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. LLY presents a […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-140055177.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c0b00bdb-3081-31d4-8e3f-7caf9bfea634",
      "content": {
        "id": "c0b00bdb-3081-31d4-8e3f-7caf9bfea634",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Eli Lilly and Company on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,039.51 as of January 27th. LLY’s trailing and forward P/E were 50.93 and 31.65 respectively according to Yahoo Finance. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. LLY presents a […]",
        "pubDate": "2026-01-28T14:00:55Z",
        "displayTime": "2026-01-28T14:00:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1282e6028bede630199849b05ea74605",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "Pharmacy, Medicines, Health",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SDromOzK6Yk2TaOlLijzbQ--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1282e6028bede630199849b05ea74605.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RdYVAkUajxTx1ngrZPN94Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1282e6028bede630199849b05ea74605.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-140055177.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-140055177.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]